Medidata, a Dassault Systèmes brand, has expanded its partnership with The Menarini Group and its subsidiary Stemline Therapeutics to accelerate oncology clinical trials using AI Study Build technology. The technology leverages data from over 38,000 trials to automate configurations, reducing the time between protocol finalisation and trial startup from months to weeks. Stemline recently launched its first oncology study entirely in-house using Medidata's platform. The AI-powered system enables rapid study startups, internal agility for building future trials independently, and faster delivery of high-quality data for cancer research. The expansion builds on a 14-year relationship between Menarini and Medidata. Whilst Menarini has long used Medidata's platform including Rave EDC and eCOA, the adoption of AI Study Build marks a significant advancement in streamlining clinical trial workflows.

Medidata, a Dassault Systèmes brand providing clinical trial solutions, has deployed AI technology across over 500 clinical studies in the past decade, with more than 120 AI-supported studies launching in 2025 alone. The company has introduced Medidata AI Study Build, which uses generative AI to configure trial systems by leveraging study protocols, significantly reducing time from protocol to start-up. The technology draws on data from more than 38,000 trials to accelerate clinical development. Medidata is expanding Dot, its AI orchestrator that connects domain-specific AI capabilities across its platform. The company's unified platform aims to streamline complex database builds and accelerate market access for new therapies. Medidata serves approximately 2,300 customers with over 1 million registered users.

Incorporating the UK integrated Costing Tool (iCT) pricing into Medidata Grants Manager is expected to amplify UK budget precision by up to 80%London – 11 Feb., 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has integrated data from the UK interactive Costing Tool (iCT ) , hosted by the National Institute for Health and Care Research (NIHR), into Medidata Grants Manager, creating a first-of-its-kind offering in the life sciences space. This will consolidate study budgeting with consistent costs, coding, and processes.“The ability for clinical trial teams to efficiently develop grant budgets and administer site negotiations is a crucial function of a trial,” said Meghan Harrington, vice president, clinical financial management, Medidata. “Incorporating the UK iCT into Grants Manager streamlines the study start up process and improves budget precision by up to 80%.”The UK approach for commercial study costing and contracting relies on a standardized budget template with specific codes and costs to ensure efficient budget preparation. The manual transfer of data from the UK iCT system into budgeting applications creates inefficiencies, including delays and duplication of efforts that increase the risk of errors. Integrating UK iCT data directly into Grants Manager overcomes these challenges by eliminating the need for manual data entry, significantly reducing preparation time and supporting data consistency across platforms.“Our overarching mission as an organization is to advance the nation’s health through groundbreaking research, and with Medidata’s support, we are proudly positioning the UK as a global leader in this endeavor,” said Laura Bousfield, national research delivery director, NIHR. “This Medidata solution empowers us to improve UK budget accuracy, creating a process that is more systematic and reliable